Mountain Crest Acquisition Corp. II (MCAD) to Combine with Better Therapeutics in $187M Deal

Mountain Crest Acquisition Corp. II (MCAD) to Combine with Better Therapeutics in $187M Deal

Mountain Crest II (NASDAQ:MCAD) has entered into a definitive agreement to combine with biopharmaceutical firm Better Therapeutics at an enterprise value of $187 million. Better Therapeutics provides prescription digital therapeutics (PDT) that deliver behavior-based therapy to address the root causes of cardiometabolic diseases. The combined company is expected to be listed on the Nasdaq under
Read More
To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.